Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Moss, Paul; Bérenbaum, Francis; Curigliano, Giuseppe; Grupper, Ayelet; Berg, Thomas; Pather, Shanti

doi:10.1016/j.vaccine.2022.05.067

Cited by 10 publications

(7 citation statements)

References 145 publications

(174 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potential strategies to increase vaccination include: (1) Emphasize the role of vaccination in decreasing the significant risk for hepatic decompensation and death associated with SARS‐CoV‐2 infection 14. (2) Normalize hesitancy and work collaboratively with patients to correct mis‐ or false information regarding vaccines' safety, authorization process, or underlying technologies 35. (3) Strengthen partnerships with vaccination programs within/between health systems and community organizations to improve timely access to vaccines 14.…”

Section: Discussionmentioning

confidence: 99%

“…[14] (2) Normalize hesitancy and work collaboratively with patients to correct mis-or false information regarding vaccines' safety, authorization process, or underlying technologies. [35] (3) Strengthen partnerships with vaccination programs within/between health systems and community organizations to improve timely access to vaccines. [14] (4) For patients who are also transplant candidates, highlight the need for vaccination before transplant because of deficient immune responses observed in the posttransplant setting.…”

Section: Hepatologymentioning

confidence: 99%

See 1 more Smart Citation

Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study

Ge¹,

Digitale²,

Pletcher³

et al. 2023

Hepatology

View full text Add to dashboard Cite

Background and Aims Outcomes of breakthrough SARS‐CoV‐2 infections have not been well‐characterized in non‐veteran vaccinated chronic liver disease (CLD) patients. We used the National COVID Cohort Collaborative (N3C) to describe these outcomes. Methods We identified all CLD patients with or without cirrhosis who had SARS‐CoV‐2 testing in the N3C Data Enclave as of 1/15/2022. We used Poisson regression to estimate incidence rates of breakthrough infections and Cox survival analyses to associate vaccination status with all‐cause mortality at 30 days among infected CLD patients. Results We isolated 278,457 total CLD patients: 43,079 (15%) vaccinated and 235,378 (85%) unvaccinated. Of 43,079 vaccinated patients, 32,838 (76%) were without cirrhosis and 10,441 (24%) with cirrhosis. Breakthrough infections incidences were 5.4 and 4.9 per 1,000 person‐months for fully vaccinated CLD patients without cirrhosis and with cirrhosis, respectively. Of the 68,048 unvaccinated and 10,441 vaccinated CLD patients with cirrhosis, 15% and 3.7%, respectively, developed SARS‐CoV‐2 infection. The 30‐day outcome of mechanical ventilation or death after SARS‐CoV‐2 infection for unvaccinated and vaccinated CLD patients with cirrhosis were 15.2% and 7.7%, respectively. Compared to unvaccinated patients with cirrhosis, full vaccination was associated with a 0.34‐times adjusted hazard of death at 30 days. Conclusions In this N3C study, breakthrough infection rates were similar amongst CLD patients with and without cirrhosis. Full vaccination was associated with a 66% reduction in risk of all‐cause mortality for breakthrough infection among CLD patients with cirrhosis. These results provide an additional impetus for increasing vaccination uptake in CLD populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Hepatologymentioning

confidence: 99%

Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study

Ge¹,

Digitale²,

Pletcher³

et al. 2023

Hepatology

View full text Add to dashboard Cite

show abstract

“… 24 Access to context-specific resources and information has the potential to alleviate some anxiety and concerns for those more vulnerable. 25 , 26 …”

Section: Discussionmentioning

confidence: 99%

Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease

Tikellis,

Corte,

Glaspole

et al. 2024

Chron Respir Dis

View full text Add to dashboard Cite

Background People with interstitial lung disease (ILD) were deemed more vulnerable to the SARS-CoV-2 virus and isolated as a means of reducing risk of infection. This study examined the impact of the pandemic on daily life, psychological wellbeing and access to healthcare and identified approaches undertaken to remain safe. Methods Four specialist clinics in tertiary centres in Australia (Victoria: two sites; New South Wales: one site; Western Australia: one site) recruited patients with ILD during an 8-week period from March 2021. Semi-structured telephone interviews were conducted with transcripts analysed using principles of grounded theory. Results Ninety participants were interviewed between April and December 2021. Participants were predominantly female, former smokers with an average age of 66 years. IPF and connective tissue-ILD being the most common subtypes. Five main themes were identified: vulnerability reduced social interaction and isolation, access to healthcare services and support, staying active, emotional and psychological impact. Self-management strategies included staying active both physically and mentally. Discussion Self-management was key to managing the impact of the pandemic. In combination with advances in technology, implementation of strategies for monitoring wellbeing and support for self-management provides an opportunity to leverage the lessons learnt to ensure a more individualised model of care for people with ILD.

show abstract

“…The use of polysorbate 80 in adenoviral vector vaccines and of polyethylene glycol (PEG) or tromethamine in mRNA vaccines raised initial concerns regarding the possibility of developing severe allergic reactions. However, these types of secondary effects were uncommon [215]. A certain degree of variability in vaccine effectiveness was observed in high-risk patients, such as immunocompromised individuals.…”

Section: Vaccine Developmentmentioning

confidence: 99%

Addressing Inequality in the COVID-19 Pandemic in Africa: A Snapshot from Clinical Symptoms to Vaccine Distribution

Pêgo,

Lima,

Gozzelino

2024

COVID

View full text Add to dashboard Cite

On 30 January 2020, WHO declared COVID-19 a public health emergency of global concern. COVID-19 became pandemic on 11 March 2020, and spread unprecedently. No country was prepared to face its impact. Major fears started to be expressed for Africa, where dramatic consequences were expected, due to the weakness of health systems. In this review, we related major concerns, at that time but still present, regarding the limited resources in terms of qualified physicians and researchers, as well as the scarce funds to purchase essential medical equipment and improve hospital infrastructures. The difficulties to provide proper care became an undeniable mark of inequality, highlighting the need to empower local capacity and raise preparedness against infection outbreaks. The transmissibility of genetic variants affecting African nations, the immunopathology underlying comorbidities, sequelae, and pre-existing conditions, often related to changes in iron metabolism and enhancing COVID-19 severity, were described. The obstacles in adopting standardized prevention measures were highlighted, along with testing capacity biases and inequity of healthcare access and vaccine distribution. By providing a better understanding of the COVID-19 pandemic in Africa, we draw attention to the need for collaborative efforts to leverage the quality of healthcare and research in this continent.

show abstract

Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest

Cited by 10 publications

References 145 publications

Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study

Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study

Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease

Addressing Inequality in the COVID-19 Pandemic in Africa: A Snapshot from Clinical Symptoms to Vaccine Distribution

Contact Info

Product

Resources

About